Bocom International: kangfang biology maintains its buying rating, with the target price rising from HK $72.50

Bocom International: kangfang biology maintains its buying rating, with the target price rising from HK $72.50
According to the report released by Bank of Communications International, the clinical progress of ak104 of kangfang biological (09926. HK) is smooth, the clinical data of phase II of the first-line treatment of unresectable liver cancer with lenvastinib is slightly improved, and the combination of ak119 (CD73) has great research and development potential. The clinical data of ak112 is encouraging. For multi drug resistant or refractory solid tumor / platinum resistant ovarian cancer, the objective response rate (ORR) is 22.2% / 38.5%, and the disease control rate (DCR) is 74.1% / 92.3%.